Excellence continues: A perfect score of 10 in the VEKTOR ranking for Antibiotice Iași, six years in a row
Antibiotice Iași scores a perfect 10 in the VEKTOR ranking for the sixth consecutive year, highlighting excellence in investor communication and openness to the capital market. The evaluation included all companies listed on the Bucharest Stock Exchange, both on the main market and the AERO market, with each evaluated based on specific criteria.
Antibiotice Iași sets excellence standards in its relationship with investors, obtaining a score of 10 for the sixth consecutive year in the VEKTOR ranking, among 81 companies evaluated on the main market. This indicator reflects the quality of interaction and transparency of companies listed on the Bucharest Stock Exchange (BVB) and is published annually on the BVB website.
VEKTOR is conducted by the Romanian Association for Investor Relations (ARIR) based on a methodology that includes 10 criteria evaluating aspects related to transparency, proactive communication with investors, and corporate governance. Antibiotice achieved maximum scores in all evaluation criteria, further solidifying its reputation as a transparent and responsible company.
The performance achieved in 2024 emphasizes Antibiotice’s commitment to the best practices in governance and investor communication.
A strong relationship with investors: a strategic priority
Over the years, Antibiotice has shown that its relationship with investors is not just a regulatory requirement but a strategic priority.
A key moment in its dialogue with the capital market was the organization of “Investor Day” events. These gatherings brought together investors, financial analysts, and company representatives, offering an opportunity to explore the company’s growth strategy, investment projects, sustainability policies, and long-term prospects.
“In an increasingly dynamic economic environment, transparency and solid governance are essential for our success on the capital market. Achieving the maximum score in VEKTOR for the sixth consecutive year underscores our commitment to responsible governance and its integration into the company’s long-term strategy. We believe that strong governance is the foundation of investor trust and sustainable development. Since 1997, when we were listed on the BVB, Antibiotice has traded over one billion shares, significantly contributing to the dynamics of the Romanian capital market. Through clear strategies and a sustainable vision, the company brings value to both shareholders and the financial community”, said Ioan Nani, General Director of Antibiotice Iași.
A significant contribution to the Romanian capital market
With nearly 28 years on the capital market, Antibiotice Iași (BVB ticker symbol ATB) remains an important player on the BVB. By the end of December 2024, the company had recorded a market capitalization of over 1.7 billion lei, confirming the stability and attractiveness of its shares to investors, as well as the market’s confidence in the company’s performance and development plans.
Looking towards the future
Antibiotice continues to strengthen its position on the Romanian capital market, while also aiming to become an example of best practices and sustainability in the pharmaceutical industry. Commitment to transparency, corporate governance, and financial performance remains a central pillar of the company’s strategy.
Through innovative initiatives and open dialogue with investors, Antibiotice demonstrates that success in the capital market is the result of a relationship based on trust, communication, and responsibility.
